Patients with axSpA, n=176 | Patients with SpA,* n=213 | Patients with PsA, n=312 | P value | |
mSASSS ≥2, n (%) | 16 (9.1) | 17 (7.9) | 33 (10.6) | 0.320 |
mSASSS, mean±SD min, 0.25, median, 0.75, max | 10.7±15.2 1-2-6-13-64 | 10.3±14.91 1-2-5-13-64 | 4.5±4.24 1-2-3-6-21 | 0.014 |
Erosions ≥1, n (%) | 3 (1.7) | 4 (1.9) | 13 (4.2) | 0.146 |
Erosions (spine), mean±SD min, 0.25, median, 0.75, max | 1±0.0 1-1-1-1-1 | 1±0.0 1-1-1-1-1 | 1.5±1.39 1-1-1-1-6 | 0.770 |
Squaring ≥1, n (%) | 4 (2.3) | 4 (1.9) | No obs. | N.A |
Squaring (spine), mean±SD min, 0.25, median, 0.75, max | 1.8±0.96 1-1-1.5-2.5-3 | 1.8±0.96 1-1-1.5-2.5-3 | No obs | N.A |
Sclerosis ≥1, n (%) | 6 (3.4) | 6 (2.8) | 2 (0.6) | 0.046 |
Sclerosis (spine), mean±SD min, 0.25, median, 0.75, max | 1.8±1.33 1-1-1-3-4 | 1.8±1.33 1-1-1-3-4 | 1.5±0.71 1-1-1.5-2-2 | 0.377 |
Syndesmophytes (total spine) ≥1, n (%) | 13 (7.4) | 14 (6.6) | 33 (10.6) | 0.115 |
Syndesmophytes (total spine), mean±SD min, 0.25, median, 0.75, max | 5.5±5.90 1-1-4-5-22 | 4.9±5.78 1-1-3.5-5-22 | 2.0±1.45 1-1-2-2-8 | 0.005 |
Syndesmophytes (cervical spine) ≥1, n (%) | 8 (4.5) | 9 (3.5) | 24 (7.7) | 0.048 |
Syndesmophytes (cervical spine), mean±SD min, 0.25, median, 0.75, max | 3.1±3.00 1-1-2.5–3.5-10 | 2.9±2.89 1-1-2-3-10 | 1.8±1.32 1-1-1-2-7 | 0.070 |
Syndesmophytes (lumbar spine) ≥1, n (%) | 10 (5.7) | 10 (4.7) | 11 (3.5) | 0.502 |
Syndesmophytes (lumbar spine), mean±SD min, 0.25, median, 0.75, max | 4.2±4.44 1-1-2-6-12 | 4.2±4.44 1-1-2-6-12 | 1.9±0.70 1-1-2-2-3 | 0.0535 |
*SpA group contains 176 patients with axial SpA and 37 peripheral patients with SpA originated from the (Be-)GIANT cohort.
†Between patients with PsA and all (axial and peripheral) patients with SpA.
axial SpA, axial spondyloarthritis; (Be-)GIANT, Ghent and BelGian Inflammatory Arthritis and spoNdylitis cohorTs; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; PsA, psoriatic arthritis; SpA, spondyloarthritis.